<DOC>
	<DOCNO>NCT02129205</DOCNO>
	<brief_summary>To assess safety tolerability increase dose level PF-06650808 patient advance solid tumor order determine maximum tolerate dose select recommend Phase 2 dose .</brief_summary>
	<brief_title>A Dose Escalation Study PF-06650808 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis advanced/metastatic solid tumor resistant standard therapy standard therapy available Previously treat metastatic triple negative breast cancer express Notch3 least one measurable lesion Adequate bone marrow , renal liver function Major surgery , radiation therapy systemic anticancer therapy within 4 week start study treatment Patients know symptomatic brain metastasis require steroid Prior treatment compound mechanism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>PF-06650808</keyword>
	<keyword>Phase 1</keyword>
</DOC>